Clayton Barbour
Internal Medicine · Cathedral City, CANPI 1326137589
Payments from drug & device makers
Across 430 payments — averaging $265.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$104K
- Theratechnologies Inc.$3K
- AbbVie$2K
- GSK$1K
- Gilead$839
- Johnson & Johnson$677
- plus $3K from 18 others
What the payments were for
- Consulting fees$24,75322%
- Speaking & faculty fees$73,25064%
- Travel & lodging$6,4536%
- Food & beverage$9,4038%
- Education$3920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 152 | $104,079 |
| Theratechnologies Inc. | 18 | $3,075 |
| AbbVie(2 entities) | 55 | $1,657 |
| GSK | 10 | $1,299 |
| Gilead | 34 | $839 |
| Johnson & Johnson(2 entities) | 43 | $677 |
| Janssen Products, LP | 5 | $518 |
| Merck | 20 | $506 |
| EMD Serono, Inc. | 33 | $475 |
| Napo Pharmaceuticals Inc | 19 | $280 |
| Antares Pharma, Inc. | 14 | $198 |
| Amgen | 5 | $136 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Novo Nordisk | 4 | $83 |
| Nestle Healthcare Nutrition Inc. | 5 | $82 |
| Scilex Pharmaceuticals Inc. | 3 | $48 |
| Alkermes, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Vyera Pharmaceuticals, LLC | 1 | $20 |
| Shionogi Inc | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Qiagen, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,251 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TivicayDolutegravir Sodium | 426 | $1,171,994 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 243 | $964,865 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 223 | $848,494 |
| DescovyEmtricitabine/Tenofov Alafenam | 290 | $632,007 |
| PrezcobixDarunavir/Cobicistat | 227 | $590,470 |
| RukobiaFostemsavir Tromethamine | 52 | $449,775 |
| JulucaDolutegravir/Rilpivirine | 131 | $444,076 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 88 | $422,999 |
| DovatoDolutegravir Sodium/Lamivudine | 132 | $410,388 |
| PifeltroDoravirine | 169 | $298,628 |
| IsentressRaltegravir Potassium | 86 | $171,600 |
| OzempicSemaglutide | 172 | $171,335 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 48 | $167,897 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 38 | $163,396 |
| Maraviroc | 113 | $129,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTivicay, Triumeq, Rukobia, Juluca, Dovato | $104,079 | $3,425,432981 claims |
| GileadBiktarvy, Descovy, Genvoya | $839 | $1,760,268571 claims |
| Johnson & JohnsonPrezcobix | $677 | $590,470227 claims |
| MerckPifeltro, Isentress, Januvia, Janumet Xr | $506 | $533,593348 claims |
| Janssen Products, LPSymtuza | $518 | $422,99988 claims |
| Novo NordiskOzempic | $83 | $171,335172 claims |
| Antares Pharma, Inc.Xyosted | $198 | $121,614192 claims |
| Napo Pharmaceuticals IncMytesi | $280 | $114,59920 claims |
| AbbVieViberzi, Creon | $1,657 | $37,90049 claims |
| GSKAnoro Ellipta | $1,299 | $19,49739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Cathedral City
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.